Effects of immunosuppressive drugs on HIV infection: Implications for solid-organ transplantation

Transplant International

Volumn 20, Issue 8, 2007, Pages 649-658

  Ciuffreda, Donatella ^a,b   Pantaleo, Giuseppe ^a   Pascual, Manuel ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Geneva Lausanne Transplantation Network   (Switzerland)

Author keywords

HAART; HIV; Immunosuppression; Organ transplantation

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; BASILIXIMAB; CYCLOSPORIN; CYCLOSPORIN A; DIDANOSINE; ENTECAVIR; HYDROXYUREA; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERLEUKIN 2; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; PEGINTERFERON; PLACEBO; RAPAMYCIN; RIBAVIRIN; RITUXIMAB; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STEROID; TENOFOVIR; THYMOCYTE ANTIBODY; UNINDEXED DRUG; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; BLOOD TOXICITY; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DRUG BINDING; DRUG EFFECT; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY TRANSPLANTATION; LIVER TOXICITY; LIVER TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; NEPHROTOXICITY; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; VIREMIA;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GRAFT REJECTION; HIV; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; VIRUS REPLICATION; WORLD HEALTH;

EID: 34347392905     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00483.x     Document Type: Review

References (80)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998 338: 853.
2. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-1998: the EuroSIDA study. Lancet 2000 356: 291.
3. del Amo J, Perez-Hoyos S, Moreno A, et al. Trends in AIDS and mortality in HIV-infected subjects with hemophilia from 1985 to 2003. The competing risks for death between AIDS and liver disease. J Acquir Immune Defic Syndr 2006 41: 624.
4. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006 194: 11.
5. Weiss RA. HIV and AIDS in relation to other pandemics. EMBO Rep 2003 4: S10.
6. Selik RM, Byers RH Jr., Dworkin MS. Trends in diseases reported on US death certificates that mentioned HIV infection 1987-1999. J Acquir Immune Defic Syndr 2002 29: 378.
7. Thio CL, Seaberq EC, Skolasky R Jr., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002 360: 1921.
8. Hayashi PH, Flynn N, McCurdy SA, Kuramoto IK, Holland PV, Zeldis JB. Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus. J Med Virol 1991 33: 177.
9. Sherman KE, Freeman S, Harrison S, Andron L. Prevalence of antibody to hepatitis C virus in patients infected with the human immunodeficiency virus. J Infect Dis 1991 163: 414.
10. Rumi MG, Colombo M, Gringeri A, Mannucci PM. High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels. Ann Intern Med 1990 112: 379.
11. Salmon-Ceron D, Gouëzel P, Delarocque-Astagneau E, et al. Hospitalized HIV-HCV co-infected patients. A French national survey made in June 2001. Med Mal Infect 2003 33: 78.
12. Staples CT Jr., Rimland D, Dudlas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veteran Affairs Medical Center) Cohort Study (HAVACS): the effect of co-infection on survival. Clin Infect Dis 1999 29: 150.
13. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005 42: 799.
14. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005 34: 121.
15. Garcia-Samaniego J, Rodriguez M, Berenguer M, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001 96: 179.
16. Bruno R, Sacchi P, Filice C, Puoti M, Filice G. Hepatocellular carcinoma in HIV infected patients with chronic hepatitis. J Acquir Immune Defic Syndr 2002 30: 535.
17. Cattelan AM, Erne E, Salatino A, et al. Severe hepatic failure related to nevirapine treatment. Clin Infect Dis 1999 29: 455.
18. Bossi P, Colin D, Bricaire F, Caumes E. Hypersensitivity syndrome associated with efavirenz therapy. Clin Infect Dis 2000 30: 227.
19. John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV infected patients with HIV protease inhibitors: an immune restoration disease AIDS 1998 12: 2289.
20. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002 186: 23.
21. Sulkowsky MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000 283: 74.
22. Gardenswartz MH, Lerner CW, Seligson GR, et al. Renal disease in patients with AIDS: a clinicopathologic study. Clin Nephrol 1984 21: 197.
23. Rao TK, Filippone EJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984 310: 669.
24. United States Renal Data System (USRDS). USRDS 2004 Annual Data Report: Atlas of End Stage Renal Disease in the United States. Bethesda, MD: The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004.
25. Winston J, Klotman P. Are we missing an epidemic of HIV associated nephropathy J Am Soc Nephrol 1996 7: 1.
26. Lam M, Park MC. HIV associated nephropathy beneficial effect of zidovudine therapy. N Engl J Med 1990 323: 1775.
27. Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of US transplant centers. Transplantation 1998 65: 1187.
28. Hirose K, Stock PG. Liver transplantation in the human immunodeficiency virus-positive patient. Curr Opin Organ Transplant 2006 11: 241.
29. Qiu J, Terasaki PI, Waki K, Cai J, Gjertson DW. HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation 2006 81: 1658.
30. Fauci AS. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1988 239: 617.
31. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile latent viral structure. Cell 1990 61: 213.
32. Pantaleo G, Graziosi C, Fauci AS. The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993 328: 327.
33. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003 21: 265.
34. Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 2001 14: 753.
35. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV specific CD4+T cells. Nature 2002 417: 95.
36. Silvestri G, Sodora DL, Koup RA, et al. Nonpathogenic SIV infection of sooty mangabeys is characterised by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003 18: 441.
37. Monceaux V, Estaquier J, Fevrier M, et al. Extensive apoptosis in lymphoid organs during primary SIV infection predicts rapid progression towards AIDS. AIDS 2003 17: 1585.
38. Silvestri G, Fedanov A, Germon S, et al. Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabeys and nonnatural rhesus macaque hosts. J Virol 2005 79: 4043.
39. Lempicki RA, Kovacs JA, Baseler MW. Impact of HIV infection and highly active antiretroviral therapy on the kinetics of CD4 and CD8 T cell turnover in HIV infected patients. Proc Natl Acad Sci USA 2000 97: 13778.
40. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997 278: 1291.
41. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997 278: 1295.
42. Pantaleo G. How immune based intervention can change HIV therapy. Nat Med 1997 3: 483.
43. Lori F, Foli A, Groff A, et al. Optimal suppression of HIV replication by low dose hydroxyurea through the combination of antiviral and cytostatic (virostatic) mechanisms. AIDS 2005 19: 1173.
44. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996, 335,18: 1350 1356.
45. Rizzardi GP, Pantaleo G. Other approaches to combat HIV-1 infection. In: Richman DD, ed. HIV Human Virus Guide 2002. London, UK: International Medical Press, 2002.
46. Luban J. Absconding with the chaperone: essential cyclophilin-Gag interaction in HIV-1 virions. Cell 1996 l87: 1157.
47. Yin L, Braaten D, Luban J. Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. J Virol 1998 72: 6430.
48. Franke EK, Yuan HEH, Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994 372: 359.
49. Thali M, Bukovsky A, Kondo E. Functional association of cyclophilin A with HIV- 1 virions. Nature 1994 372: 363.
50. Bartz SR, Hohenwalter E, Hu MK, Rich DH, Malkovsky M. Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A. Proc Natl Acad Sci USA 1995 92: 5381.
51. Franke EK, Luban J. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology 1996 222: 279.
52. Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E, Crabtree GR. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 1989 246: 1617.
53. Streblow DN, Kitabwalla M, Malkovsky M, Pauza CD. Cyclophilin a modulates processing of human immunodeficiency virus type 1 p55Gag: mechanism for antiviral effects of cyclosporin A. Virology 1998 245: 197.
54. Rizzardi GP, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002 109: 681.
55. Khonkarly M, Tambussi G, Ciuffreda D, et al. Long term benefit of cyclosporin A coupled with highly active antiretroviral therapy in primary HIV-1 infection. Conference on Retroviruses and Opportunistic Infections, Boston, 2005.
56. Calabrese LH, Lederman MM, Spritzler J, et al. Placebo-controlled trial of cyclosporin A in HIV disease: implications for solid organ transplantation. J Acquir Immune Defic Syndr 2002 29: 356.
57. Allison AC, Kowalski WJ, Muller CD, Eugui EM. Mechanisms of action of mycophenolic acid. Ann N Y Acad Sci 1993 696: 63.
58. Allison AC, Almquist SJ, Muller CD, Eugui EM. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc 1991 23: 10.
59. Ichimura H, Levy JA. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 1995 211: 554.
60. Gao WY, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in Peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993 90: 8925.
61. Margolis D, Heredia A, Gaywee J, et al. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr 1999 21: 362 370.
62. Heredia A, Margolis D, Oldach D, Hazen R, Le N, Redfield R. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. J Acquir Immune Defic Syndr 1999 22: 406.
63. Hossain M, Coull J, Drusano GL, Margolis M. Dose proportional inhibition of HIV1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine and tenofovir. Antiviral Res 2002, 55: 41.
64. Margolis DM, Kewn S, Coull JJ, et al. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2002 31: 45.
65. Sankatsing SU, Jurriaans S, van Swieten P, et al. Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naïve HIV-1 patients. AIDS 2004 18: 1925.
66. Chapuis A, Rizzardi GP, D'Agostino C, et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2001 6: 762.
67. Ciuffreda D. Abstract 104: Single supervised treatment interruption coupled with mycophenolate mofetil therapy induces control of HIV 1 RNA replication in patients treated with HAART since primary HIV1 infection: 102 week follow up. Conference on Retroviruses and opportunistic agents, Boston, February 2005.
68. Ragni MV, Belle SH, Im K, et al. Survival of human immunodeficiency virus- infected liver transplant recipients. J Infect Dis 2003 188: 1412.
69. Norris S, Taylor C, Muiesan P, et al. Outcomes of liver transplantation in HIV- infected individuals: the impact of HCV and HBV infection. Liver Transpl 2004 10: 1271.
70. Vogel M, Voigt E, Schäfer N, et al. Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: outcome of 7 patients from the Bonn cohort. Liver Transpl 2005 11: 1515.
71. Stock PG, Roland ME, Carlson LL, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003 76: 370.
72. Wolters L, Niesters H, Hansen B, et al. Development of hepatitis B resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol 2002 24: 173.
73. Benhamou Y, Bochet M, Thibault V, et al. Long term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999 30: 1302.
74. Wiegand J, Tischendorf J, Nashan B, et al. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. Gastroenterology 2004 42: 15.
75. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003 348: 177.
76. Schiff E, Lai C, Hadziyannis S, Neuhaus P, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003 38: 1419.
77. Terrault N, Carter JT, Carlson L, Roland ME, Stock PG. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl 2006 12: 801.
78. Kumar MSA, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV positive patients. Kidney Int 2005 67: 1662.
79. Carter JT, Melcher ML, Carlson LL, Roland ME, Stock PG. Thymoglobulin-associated Cd4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant 2006 6: 753.
80. Brandao AB, Mariante-Neto G. Liver transplantation in HIV-positive patients: the position of the Brazilian groups. Arq Gastroenterol 2005 42: 161.